Condition (MeSH)
IgA Vasculitis
ClinicalTrials.gov lists 33 trials for IgA Vasculitis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
33 of the 33 trials are tagged with IgA Vasculitis itself; the rest are tagged with a narrower condition beneath it.
When did IgA Vasculitis trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 2 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are IgA Vasculitis trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 5 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 7 |
| Observational | 16 |
How many IgA Vasculitis trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 11 |
| Completed | 13 |
| Terminated | 1 |
| Unknown status | 7 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most IgA Vasculitis trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 1 |
| Bursa City Hospital | 1 |
Which drugs are being tested for IgA Vasculitis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RITUXIMAB | 2 |
| Cytoxan | 2 |
| METHYLPREDNISOLONE | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Colchicines | 2 |
| Autologous Peripheral Blood Stem Cell Transplantation | 1 |
| BLOOD SAMPLES | 1 |
| Gamma Globulin | 1 |
| Oral prednisolone and SoC | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do IgA Vasculitis trials report? (8)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cellulitis | 1 | 1 |
| Myocardial infarction | 1 | 1 |
| Oral candidiasis | 1 | 1 |
| Polychondritis | 1 | 1 |
| Septic shock | 1 | 1 |
Showing 5 of 8 adverse events.
Which publications cover IgA Vasculitis? (28)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Telitacicept use in children with IgA vasculitis nephritis: preliminary observations. | Pediatric nephrology (Berlin, Germany) | 2025 | Yes |
| Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis. | Pediatric nephrology (Berlin, Germany) | 2025 | Yes |
| Interventions for preventing and treating kidney disease in IgA vasculitis. | The Cochrane database of systematic reviews | 2023 | Yes |
| Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | 2020 | Yes |
| Indications and efficiency of dapsone in IgA vasculitis (Henoch-Schonlein purpura): case series and a review of the literature. | European journal of pediatrics | 2019 | Yes |
Showing 5 of 28 publications.
Prevalence (24)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Immunoglobulin A vasculitis | Annual incidence | 1-5 / 10 000 | United Kingdom | GB | Exact |
| Immunoglobulin A vasculitis | Annual incidence | 1-5 / 10 000 | United Kingdom | GB | Exact |
| Immunoglobulin A vasculitis | Annual incidence | 1-5 / 10 000 | United Kingdom | GB | Unspecified |
| Immunoglobulin A vasculitis | Annual incidence | 1-9 / 100 000 | Croatia | Not stated | Exact |
| Immunoglobulin A vasculitis | Annual incidence | 1-9 / 100 000 | Croatia | Not stated | Exact |
Showing 5 of 24 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Immunoglobulin A vasculitis | 761 | Exact | Orphadata Science knowledge files, Product 1 |
| Immunoglobulin A vasculitis | 761 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.